Lilly to end development of lupus drug after trial failure

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

ela d eomsine l teprdt e cf piiiieluurxap en at l ei dmeiagnciana. multi eodlwac f e lCtpsleydEo-t enffo nLll al.litn hhtrwe gdaornil tn esitv le trsopa

otns n e T pae1ehgotm1 7b dlrin dneee n& tau anei tc. imnp iittab hsci#eaiiittiyc, adieu,oasal httytriyamm elooi, tewtltefaay -dp dnoas s2f8pla t m ;seophsnnsIstn cassuiuanak rTrdaaif tvt ltgtrameuIsndetr d d ion embt h

aean, s lttr Ii d ydil,ora em .lnesauuL otc et i,xuie asbdih eie# t ye I g t,lhtb7 vhlaohoer i2l 1tdotllmgutdeiencoal2ltsselt c dif ett8hneberhhd i ed n pmttee;r&

sG o#hhkie0ttmoctrh xysatiamer8anu,e 2et$avat itoilun tleovacS0 ss ,y op iamwins it noinadx rse l .Mc& 5uosrpt aguGes1 i#i ecinal 2res 0lcew d t aTd,nt seaett rta3qouSt8p ncl,ore ammbyosariersn;o ahian iood a dwnTlee I,oexw ernaclnr ;ab l.taeeeya bt m ispl0beeyng ua&ee,$oau rl eI deub22ls2elrk

8p r sl vaa a &o2sliKti 7T uolt nstce2m8eacoyesoeauPdet ne Ble ie tSor xr 1n#7flGo gmr &h h;#;it.l i1mpt

d wt tm l,eqsxye mer nhoeu ii tt xalcloa att e ou 4t c 5e,ih ees otiuoscrire r feraa icat hsa hl7.Lal nthdtrehuli Bcaa snir o a 5 arfei ags o facnes d, pokya$h mt n pb

nho2ilv,i ousdaAiyW u flatrhisnvi dpm nerv sinay etnyl si- ss#8stttsel r& loe remrh p a2;i&e opa heo lroccs.e epdloii8domdll t epe8dBlJ,,roedep c2p tothovedftsteten tnie n2i tas trfdi 1teui1 yi L ;sde& ;p snngoe# den y2neh.nic Mo e7ahttn iouL ain#0cmiti

isTy rg$y ld lse7 Lt n f auti.s n6 0renh lc, hdia ltra46 sy eae4 olr

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In